Melanoma & Skin

  • EA6134 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
  • S1616 Ipilimumab With or Without Nivolumab in Treating Patients with Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery  
  • S1801 A Phase II Randomized Study of Adjuvant Vs. Neoadjuvant MK-3475 (Pembrolizumab) for clinically Detectable Stage III-IV High Risk Melanoma
  • A091605  A Randomized Phase II Study of anti-PD1 antibody (Pembrolizumab) alone versus anti-PD1 antibody plus stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma
  • EA6174  STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III trial
  • A091802   Phase II Randomized trial of Avelumab Plus Cetuximab versus Avelumab alone in advanced cutaneous squamous cell carcinoma of the skin